Journal
LEUKEMIA RESEARCH
Volume 34, Issue 2, Pages 196-202Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.leukres.2009.07.020
Keywords
Acute myeloid leukemia; Cediranib; Angiogenesis; Vascular endothelial growth factor
Categories
Funding
- AstraZeneca
Ask authors/readers for more resources
VEGFR and c-Kit signaling pathways may contribute to the pathophysiology of acute myeloid leukemia (AML). Thirty-five patients with AML received cediranib (RECENTIN (TM)), an oral, highly potent VEGF signaling inhibitor with c-Kit activity, at doses of <= 30 mg/day. The most common adverse events were diarrhea, hypertension and fatigue. Six patients experienced an objective response (3 each at 20 and 30 mg). Dose- and time-dependent reductions in sVEGFR-2 were observed, and there was a positive correlation between cediranib exposure and the change in plasma VEGF levels from baseline. Cediranib was generally well tolerated and showed preliminary evidence of activity as a monotherapy. (C) 2009 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available